Omrix Biopharmaceuticals develops novel medical technologies to provide safe and effective options in areas where there are substantial unmet needs, particularly in the areas of biosurgical products and passive immunotherapy products. With its acquisition in 2009, Omrix is able to leverage Ethicon’s worldwide scope in bringing innovative new technologies to patients.

Omrix’s leadership in biosurgical expertise comes to life through a line of products that are used for the control of bleeding, or hemostasis, and other surgical applications.

Ethicon is currently marketing several products created using Omrix technology: EVICEL® Fibrin Sealant (Human), EVITHROM® Thrombin, Topical (Human), and SURGIFLO® Hemostatic Matrix. For more information on these products, including the prescribing information, please visit Ethicon360.com.

If you have questions about Omrix Biopharmaceuticals, please click here for contact information.